Long-term follow-up of an eortc randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer

Urology

Volumn 52, Issue 3, 1998, Pages 403-410

  Witjes, J A ^a   Meijden, A P M V D ^b   Collette, L ^b   Sylvester, R ^b   Debruyne, F M J ^b   Van Aubel, A ^b   Witjes, W P J ^b   Boeken Kruger, ^b   Van Aubel, ^b   Carpentier, ^b   De Wall, ^b   Oosterlinck, ^b   Bouffioux, ^b   Denis, L ^b   Keuppens, F ^b   Casselman, J ^b   Carpentier, P ^b   Newling, D ^b   Karthaus, P ^b   Sleijfer, ^b   Schroder F ^b   Van Der Meijden, A ^b   Leisenger, ^b   Bressel, ^b   Ay, ^b   Hall, R ^b   Hetherington, J ^b   Wallace, ^b   Bartsch, ^b   Hanus, ^b   De Graaf, ^b   Alleman, ^b   Kapper, ^b   Khoe, G S S ^b   Hoekstra, ^b   Schreinemachers, ^b   Debruyne, ^b   Meuleman, ^b   Maseland, ^b   De Vlaam, ^b   Weijtingh, ^b   In Den Bosch, ^b   Knol, ^b   Dijkman, ^b   Scheepers, ^b   Weyer, ^b   Delaere, ^b   Langemeyer, ^b   Ferwerda, ^b   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; MITOMYCIN C; THIOTEPA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CYSTITIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0032169530     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00212-X     Document Type: Article

References (22)

1. 1. Lamm DL, Steg A, Boccon-Gibod L, et al: Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 310: 335-355, 1989.
2. 2. Pagano F, Bassi P, Piazza N, et al: Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27(suppl 1): 19-22, 1995.
3. 3. Martinez-Pineiro JA, Solsona E, Flores N, et al, for the Cooperative Group CUETO: Improving the safety of BCG immunotherapy by dose reduction. Eur Urol 27(suppl 1): 13-18, 1995.
4. 4. Corti Ortiz D, Rivera Garay P, Aviles Jasse J, et al: Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses. Acta Urol Esp 17: 239-242, 1993.
5. 5. Mack D, and Frick J: Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in highrisk superficial bladder cancer. Urology 45: 958-961, 1995.
6. 6. Vegt PDJ, van der Meijden APM, Sylvester R, et al: Does isoniazid reduce side effects of intravesical bacillus Calmette Guerin therapy in superficial bladder cancer? Interim results of EORTC protocol 30911. J Urol 157: 1246-1249, 1997.
7. 7. Van Vooren JP, Zlotta AR, Drowart A, et al: Culture filtrate from bacillus Calmette-Guerin (BCG) is as effective as live BCG to enhance lymphocyte-mediated bladder tumour cell killing in man and in mice (abstract). J Urol 156: 383, 1997.
8. 8. Morales A, and Chin JL: Mycobacterial cell wall (MCW) as an alternative to BCG in the treatment of carcinoma in situ (CIS) of bladder: an efficacy study (abstract). J Urol 157: 214, 1997.
9. 9. Witjes JA, Oosterhof GON, and Debruyne FMJ: Management of superficial bladder cancer Ta/T1/Tis: intravesical chemotherapy, in Vogelzang NJ, Scardino PT, Shipley WU, et al (Eds): Comprehensive Textbook of Genito-Urinary Oncology. Baltimore, Williams & Wilkins, 1996, pp 416-427.
10. 10. Pawinski A, Sylvester R, Kurth KH, et al: A combined analysis of EORTC and MRC clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156: 1934-1941, 1996.
11. 11. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573-580, 1992.
12. 12. Debruyne FMJ, van der Meijden APM, Witjes JA, et al: Bacillus Calmette-Guerin versus Mitomycin-C intravesical therapy in superficial bladder cancer: results of a randomized trial after 21 months of follow up. Urology 40(suppl): 11-15, 1992.
13. 13. Debruyne FMJ, van der Meijden APM, Geboers ADH, et al: BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer: first results of randomized prospective trial. Urology 31(suppl): 20-25, 1988.
14. 14. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
15. 15. Mantel N: Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58: 690-700, 1963.
16. 16. Lundholm C, Norlen BJ, Ekman P, et al: A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156: 372-376, 1996.
17. 17. Rintala E, Jauhiainen K, Alfthan O, et al: Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette Guerin) in superficial bladder cancer. Eur Urol 20: 19-25, 1991.
18. 18. Lamm DL, Blumenstein B, Crawford ED, et al: Randomized intergroup comparison of bacillus Calmette Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol 1: 119-126, 1995.
19. 19. Zhang S, Li H, and Cheng H: The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer. Chung Hua Wai Ko Tsa Chih 33: 304-6, 1995.
20. 20. Krege S, Otto T, Rubben H, et al: Final report on a randomized multicentre trial on adjuvant therapy in superficial bladder cancer: TUR only vs TUR + mitomycin vs TUR + Bacillus Calmette Guerin (abstract). J Urol 155: 494A, 1996.
21. 21. Witjes JA, van der Meijden APM, Witjes WPJ, et al: A randomized prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder: intravesical instillations in superficial bladder cancer. Eur J Cancer 29A: 1672-1676, 1993.
22. 22. Vegt PDJ, Witjes JA, Witjes WPJ, et al: A randomized study of intravesical Mitomycin-C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153: 929-933, 1995.